Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04597879
Other study ID # 2020-A00183-36
Secondary ID 38RC20.014
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date March 31, 2023

Study information

Verified date October 2022
Source University Hospital, Grenoble
Contact Jean-Luc Cracowski, Pr
Phone 0476767856
Email JLCracowski@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Severe brain injury (SBI) is one of the world's leading causes of death and disability in young adults, but its peripheral vascular consequences in humans are poorly understood. This prospective, monocentric, pathophysiological study aims to investigate differences in vasoreactivity in the anterior aspect of the contralateral forearm at the most injured cerebral hemisphere between patients with severe head trauma and patients with severe trauma without associated brain injury matched on sex and age (+/- 5 years).


Description:

Severe brain injury (SBI) is one of the world's leading causes of death and disability in young adults. Its impact on cerebral vascularization is well known. At the systemic level, it induces transient dysfunctions that can develop into severe failures, even in cases of isolated SBI. Studies on a mouse model of SBI show alterations in peripheral vascular reactivity that persist over time and are linked to endothelial dysfunction, the mechanism of which is a decoupling of endothelial NO synthase in a context of systemic inflammation. However, no data are available regarding the peripheral vascular consequences of SBI in humans. The main objective of this prospective, monocentric, pathophysiological study is to determine whether the postocclusive hyperaemic response at the anterior surface of the contralateral forearm to the most injured cerebral hemisphere differs between patients with severe brain injury and patients with severe trauma without associated head injury matched on sex and age (+/- 5 years), by studying the amplitude of post-occlusive hyperaemia (maximum amplitude expressed as percentage of vasodilatation and area under the curve : AUC) as a function of the group.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 31, 2023
Est. primary completion date August 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Healthy volunteers : - Men and women, over 18 years of age - Affiliation to a social security scheme - Signed Consent Patients with Severe Brain Injury : - Male and female, over 18 years of age - Isolated severe brain injury, defined by an initial Glasgow score less than or equal to 8. - Affiliation to a social security scheme - Signed informed consent Severe traumatized patients without associated severe brain injury: - men and women, over 18 years of age - severe trauma, defined by an Injury Severity Score (ISS) = 16. - absence of associated severe brain injury, defined by an initial Glasgow score less than or equal to 8. - affiliation to or beneficiary of a social security scheme - signed informed consent Exclusion Criteria: - Hypersensitivity to lidocaine and/or prilocaine or to amide type local anesthetics or to any of the excipients of the cream. - History of axillary lymph node dissection, trauma or axillary surgery - Prohibited treatments and procedures : - In patients with head trauma: ongoing treatment with systemic vasodilators (calcium channel blocker, milrinone). - In healthy volunteers: no treatment will be authorized other than paracetamol, hormone supplementation (contraceptive pill, hormone therapy, thyroid hormones). - Pregnant, parturient or breastfeeding women - Subject in a period of exclusion from another study, - Person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure, - Subject having exceeded the annual compensation threshold for testing - Subject cannot be contacted in case of emergency

Study Design


Locations

Country Name City State
France University Hospital Grenoble

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-occlusive hyperaemia Maximum amplitude expressed as percentage of vasodilation and area under the curve: AUC 0-60 days
Secondary Post-occlusive hyperaemia with local anesthesia Maximum amplitude expressed as percentage of vasodilation and area under the curve: AUC 0-60 days
Secondary Current-Induced Hyperaemia Area under the curve expressed as a percentage of the baseline. 0-60 days
Secondary Current-Induced Hyperaemia with local anesthesia Area under the curve expressed as a percentage of the baseline. 0-60 days
Secondary Local thermal hyperaemia Maximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau. 0-60 days
Secondary Local thermal hyperaemia with local anesthesia Maximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau. 0-60 days
Secondary Flow amplitude after local cooling Amplitude of initial vasoconstriction averaged over 1 min around the lowest flow value during the first 5 minutes. 0-60 days
Secondary Transient venous post-compression hyperaemia Area under the curve and percentage change from baseline. 0-60 days
Secondary Study of vasoreactivity in patients with severe brain injury Extent of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in patients with severe brain injury. 0-60 days
Secondary Study of vasoreactivity in healthy subjects Description of the magnitude of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in healthy subjects. Study visit
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Terminated NCT03781817 - Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures Phase 4
Completed NCT04342416 - Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women N/A
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Recruiting NCT04725721 - Testing FIRST in Youth Outpatient Psychotherapy N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Withdrawn NCT03249129 - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed NCT02240732 - Surgical Tourniquets and Cerebral Emboli N/A
Completed NCT02227979 - Effects of PURPLE Cry Intervention N/A
Withdrawn NCT01169025 - Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT03112304 - Child STEPS for Youth Mental Health in Maine Sustainability N/A
Completed NCT01475344 - Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Phase 1/Phase 2
Completed NCT01210417 - Trauma Heart to Arm Time N/A
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4